XNK THERAPEUTICS
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden
XNK THERAPEUTICS
Social Links:
Industry:
Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Huddinge, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.xnktherapeutics.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
196 M SEK
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Investors List
Flerie Invest
Flerie Invest investment in Venture Round - XNK Therapeutics
Official Site Inspections
http://www.xnktherapeutics.com
Unable to get host informations!!!
More informations about "XNK Therapeutics"
XNK Therapeutics - Crunchbase Company Profile
Contact Email [email protected] XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a …See details»
XNK Therapeutics - LinkedIn
XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies.See details»
Agneta Edberg appointed to board of XNK Therapeutics
May 7, 2018 XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors. Agneta Edberg has over 25 years’ …See details»
company’s board of directors Ted’s combination with Sanofi’
XNK Therapeutics AB [email protected] Hälsovägen 7, Novum xnktherapeutics.com SE-141 57 Huddinge The favorable and intense start to the year continued in the second quarter …See details»
XNK Therapeutics - Company Profile & Staff Directory - ContactOut
XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet …See details»
2022, a year of growth! - XNK Therapeutics
XNK Therapeutics AB [email protected] Hälsovägen 7, Novum xnktherapeutics.com SE-141 57 Huddinge . 2022, a year of growth! We can look back on yet another eventful and …See details»
XNK Therapeutics - Overview, News & Similar companies - ZoomInfo
Nov 9, 2023 The presentation is followed by a short Q&A session, moderated by a DNB analyst. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 …See details»
XNK Therapeutics - PitchBook
XNK Therapeutics General Information Description. Operator of a clinical-stage biotechnology company intended to prevent and treat cancer in patients. The company's platform created …See details»
XNK Therapeutics AB - Drug pipelines, Patents, Clinical trials
Explore XNK Therapeutics AB with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 33 news, and 1 literature, Disease Domain:Neoplasms, Hemic and Lymphatic …See details»
XNK Therapeutics - Craft
XNK Therapeutics has 5 employees at their 1 location. See insights on XNK Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
XNK Therapeutics receives EMA scientific recommendation for ...
Jan 15, 2024 XNK Therapeutics AB ('XNK') today announced that evencaleucel has received a scientific recommendation from the Committee for Advanced Therapies (CAT) of the European …See details»
XNK Therapeutics enters into agreement with US-based …
HUDDINGE, Sweden, Aug. 10, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that the company has entered into an agreement with a US biotechnology …See details»
XNK Therapeutics strengthens its scientific network with two more …
Hälsovägen 7, Novum xnktherapeutics.com SE-141 57 Huddinge XNK Therapeutics strengthens its scientific network with two more advisors December 20th, 2021 XNK Therapeutics AB …See details»
First patient cells collected in XNK's preclinical bladder ... - BioSpace
Dec 15, 2022 According to the World Health Organization over 570,000 new cases of bladder cancer was diagnosed in 2020 globally. It is the 4 th most common form of cancer in men and …See details»
XNK Therapeutics receives US orphan drug status for NK cell …
STOCKHOLM, Nov. 4, 2020 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration …See details»
XNK Therapeutics Enters into Research Agreement with Global …
HUDDINGE, Sweden, May 4, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that the company's autologous natural killer (NK) cell therapy candidate XNK04 …See details»
XNK Therapeutics joins Vinnova’s NextGenNK competence center
Jan 31, 2020 XNK Therapeutics AB (“XNK”) today announced it joined Sweden’s Innovation Agency’s NextGenNK competence center for the development of next-generation natural killer …See details»
XNK Therapeutics to present two abstracts at the Society for ...
Aug 7, 2023 For more info, please visit www.xnktherapeutics.com About Bladder Cancer According to the World Health Organization over 570,000 new cases of bladder cancer was …See details»
Learn about NK cells – XNK Therapeutics
Learn the basics about NK cells from our 2023 NK Cell Summer School Download PDFSee details»
XNK Therapeutics raises SEK 132 million to accelerate growth - PR …
STOCKHOLM, March 29, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced it has secured a private placement of SEK 132 million, to existing and new investors, led by …See details»